ClinicalTrials.gg
RecruitingNCT07342023BACHUSUpdated Oct 26, 2026

Contribution of GFAP and UCH-L1 Assays in Whole Blood to Optimizing Personalized Care for "Repeated Fallers" Hospitalized in Geriatric Wards

An interventional study of blood sampling in Fallers Aged 60 Years and Older, Biomarkers / Blood and Intracranial Bleeding, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
770
Allocation
Not applicable
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Intracranial Hemorrhages with a site in France — 5 open to participants now, 5 under way, none of them phase 3. Intracranial Hemorrhages · France.

Planned enrollment
2nd of 11
770 · median 226
Started
2026
with 1 other
No phase
5 of 19
2 open now
Registered
18th of 19
by date
Lead sponsor
2 of 19
University Hospital, Clermont-Ferrand

Among the 19 studies in Intracranial Hemorrhages with a site in France, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 with no phase, and was the 18th registered.

Intracranial Hemorrhages

211 studies on the registry are indexed under Intracranial Hemorrhages; 62 are open to participants now.

Browse Intracranial Hemorrhages studies →

Open to participants now

5 of the 19 studies in Intracranial Hemorrhages with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 43 Intracranial Hemorrhages studies recruiting now, 27 (63%) set no upper age limit and 5 (12%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Intracranial Hemorrhages with a site in France, or all of them as a file.
02

Study summary

The BACHUS study focuses on a population of patients aged 75 years and older who are hospitalized after recurrent falls. The objective is to evaluate the performance of an innovative, personalized biological screening strategy to detect intracranial hemorrhages, as an alternative to brain CT scanning, which is often difficult to access within the required time frame in elderly patients.

Patients included in the study will undergo two blood measurements of the biomarkers GFAP and UCH-L1 performed on whole blood using a portable device such as the i-Stat Alinity. The first measurement will be performed within 72 hours of admission in order to establish an individual baseline value, given the impossibility of relying on average reference values in this population, which is subject to variability in biomarker levels due to confounding factors.

In the event of a new fall during hospitalization, and when a brain CT scan is deemed necessary by the referring physician, a second measurement will be performed within the time window recommended by the French National Authority for Health (HAS) (6 to 12 hours after the fall), ideally before the CT scan. Apart from the addition of this blood sample, the study will not modify usual patient management, with the decision to perform a CT scan remaining at the clinician's discretion.

The primary endpoint is the diagnostic performance of this personalized strategy (sensitivity, specificity, predictive values) compared with brain CT scanning, which remains the reference standard. The results will make it possible to estimate the number of CT scans that could be avoided. Secondary endpoints will allow further refinement of the analysis according to patient profile (age, sex, cognitive status, anticoagulant therapy, nutritional status, etc.).

03

Conditions studied

  • Fallers Aged 60 Years and Older
  • Biomarkers / Blood
  • Intracranial Bleeding
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized patients aged 75 years and older, cared for in the short-stay geriatric unit at Guy Thomas Hospital in Riom
  • Recurrent fallers (more than one fall per week)
  • from the patient or their designated representative for patients unable to write but capable of understanding and consenting to participate in the study
  • Enrollment in a Social Security health insurance scheme

Exclusion criteria

Exclusion Criteria:

  • Fall occurring before the reference biomarker measurement
  • Presence of an intracranial hemorrhage confirmed by CT scan at admission
  • Ischemic or hemorrhagic stroke
  • Inability to perform the two blood samples required by the protocol due to very limited venous access
  • End-of-life situation
  • Adults under legal protection (guardianship, curatorship, deprivation of liberty, or judicial protection)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
770 participants (estimated)

Study arms

  • Experimental
    One arm

    The BACHUS study, a prospective single-center study, focuses on a population of patients aged 75 years and older who are hospitalized after recurrent falls. The objective is to evaluate the performance of an innovative, personalized biological screening strategy to detect intracranial hemorrhages, as an alternative to brain CT scanning, which is often difficult to access within the required time frame in elderly patients. Patients included in the study will undergo two blood measurements of the biomarkers GFAP and UCH-L1, performed on whole blood using a portable device such as the i-Stat Alinity.

    Diagnostic Test: blood sampling

Interventions

  • Diagnostic testblood sampling

    Patients included in the study will undergo two blood measurements of the biomarkers GFAP and UCH-L1 performed on whole blood using a portable device such as the i-Stat Alinity®. The first measurement will be performed within 72 hours of admission to establish an individual baseline value. After a fall with confirmed or suspected head trauma, when a brain CT scan is deemed necessary by the referring physician, a new measurement of GFAP and UCH-L1 biomarkers will be performed on whole blood, preferably before transfer to the CT scanner, ideally between 6 and 12 hours after the fall according to HAS recommendations, followed by the brain CT scan to detect any intracranial bleeding.

06

What researchers measure

Primary outcomes

  1. Determination of the specificity, sensitivity, positive predictive value, and negative predictive value of the personalized biological strategy

    Establishment of the clinical performance of a personalized biological strategy based on the combined measurement of the biomarkers GFAP and UCH-L1 in whole blood for the detection of intracranial hemorrhages in hospitalized patients aged 75 years and older with recurrent falls.

    Time frame: From enrollment until the end of hospitalization, for a maximum duration of 28 days

Secondary outcomes

  1. Clinical performance according to patient characteristics: stratification

    Determination of the clinical performance of the personalized biological strategy according to the following criteria: sex, age group (75-85 years; 85-95 years; over 95 years), cognitive impairment, presence of anticoagulant therapy, nutritional status, renal impairment, fall-risk profile, or characteristics of intracranial hemorrhages.

    Time frame: From enrollment until the end of hospitalization, for a maximum duration of 28 days.

  2. Analysis of the organizational impact

    Estimation of the number of negative brain CT scans that could be avoided using the personalized biological strategy, compared with the conventional CT-based strategy

    Time frame: From enrollment until the end of hospitalization, for a maximum duration of 28 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Aug 2027, 17 months after the start.

Of 34 interventional studies with no phase under Intracranial Hemorrhages, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 73. This study's planned 17 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Mar 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 15, 2026
StartActual
Mar 1, 2026was Jan 2026
Primary completionEst.
Aug 2027
CompletionEst.
Aug 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
Ch de Riom is now Recruiting
Oct 26, 2026
Start date
Jan 2026→Mar 1, 2026 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    Ch de Riom is now Recruiting
    Start date Jan 2026→Mar 1, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07342023
Collaborators
CH Riom
Responsible party
Sponsor
First posted
Jan 15, 2026
Start date
Mar 1, 2026
Primary completion
Aug 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Lise Laclautre
Contact
promo_interne_drci@chu-clermontferrand.fr
+33473751195
Clément Lahaye
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion